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CD91 Is a Common Receptor
for Heat Shock Proteins
gp96, hsp90, hsp70, and Calreticulin
recently identified the a2 macroglobulin receptor CD91
as the receptor for gp96 (Binder et al., 2000a); gp96
molecules bind directly to CD91, and antibodies to CD91
inhibit re-presentation of gp96-chaperoned peptides by
APCs. Further, a2 macroglobulin, a previously known
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University of Connecticut School of Medicine ligand for CD91, inhibits re-presentation of gp96-chap-
eroned peptides by APCs. The mechanisms throughMC1601
Farmington, Connecticut 06030 which HSPs other than gp96 elicit immune responses
have not been defined explicitly, although it was origi-
nally expected that broadly similar mechanisms must
be involved. Indeed, Castellino et al. have shown re-Summary
cently that hsp70-peptide complexes are also taken up
through a receptor-like mechanism (Castellino et al.,Complexes of the heat shock protein gp96 and anti-
genic peptides are taken up by antigen-presenting 2000).
The variety of HSPs that can chaperone peptides andcells and presented by MHC class I molecules. In order
to explain the unusual efficiency of this process, the immunize, as well as the broad array of peptides that
they can chaperone, has been a continuing strength, asuptake of gp96 had been postulated to occur through
a receptor, identified recently as CD91. We show here well as a riddle, in the understanding of this pathway. We
report here certain observations that provide a commonthat complexes of peptides with heat shock proteins
hsp90, calreticulin, and hsp70 are also taken up by mechanism through which various HSPs chaperoning
an extremely small quantity of peptides elicit antigen-macrophages and dendritic cells and re-presented by
MHC class I molecules. All heat shock proteins utilize specific immunity. We show that re-presentation of
HSP-chaperoned peptides by APCs functions in athe CD91 receptor, even though some of the proteins
have no homology with each other. Postuptake pro- broadly similar manner for all HSPs tested, that all HSPs
tested appear to utilize a common CD91 receptor, andcessing of gp96-chaperoned peptides requires pro-
teasomes and the transporters associated with anti- that all HSPs tested can utilize a variety of APCs at
various stages of differentiation (including an immortal-gen processing, utilizing the classical endogenous
antigen presentation pathway. ized cultured macrophage line), each of which can re-
present HSP-chaperoned peptides. These studies also
show that re-presentation of gp96-chaperoned pep-Introduction
tides, like that of hsp70-chaperoned peptides, follows
the classical proteasome-dependent, transporter asso-Purified preparations of heat shock proteins (HSPs)
hsp70 and hsp90 of the cytosol and gp96 and calreticulin ciated with antigen processing (TAP)-dependent path-
way of presentation of endogenous antigens by MHC(CRT) of the endoplasmic reticulum have been shown
to elicit antigen-specific cellular immunity upon immuni- class I molecules.
As HSPs are released from cells as a result of necroticzation (reviewed in Srivastava et al., 1998; Basu and
Srivastava, 1999). The observed immunogenicity of HSP but not apoptotic death (Basu et al., 2000), their ability
to mediate re-presentation of antigens by APCs (Sutopreparations has been shown to derive from the anti-
genic peptides chaperoned by the HSPs. HSP-peptide and Srivastava, 1995) potentially provides a general
pathway through which antigens of cancers or infectiouscomplexes can also be reconstituted in vitro by com-
plexing a given peptide with hsp70, gp96, or CRT (Blach- agents from parenchymatous cells are cross-presented
by the APCs to naive T cells in the lymph nodes (Bevan,ere et al., 1997; Basu and Srivastava, 1999), and such
complexes are immunogenic in the same manner as the 1976). An increased understanding of this process may
therefore open the way to a deeper revelation of funda-HSP-peptide complexes generated in vivo. As little as
a few picograms of antigenic peptides are immunogenic mental immunological processes.
if complexed to the HSPs but not to non-HSP peptide
binding proteins such as albumin (Blachere et al., 1997). Results
Further, the immunogenicity of gp96-peptide complexes
has been shown to be dependent on the presence of Binding of Fluorescence-Labeled HSPs
functional antigen-presenting cells (APCs), and abroga- and a2 Macroglobulin to a Panel
tion of their function renders mice incapable of being of Primary and Cultured Cells
immunized with gp96-peptide complexes (Udono et al., FITC-labeled HSPs, gp96, hsp90, or hsp70, or control
1994). The above two observations led to the suggestion non-HSP serum albumin (SA) were incubated with primary
that APCs express receptors for HSPs and that the re- cells (peritoneal macrophage, bone marrow–derived den-
ceptors are responsible for the extremely high adjuvan- dritic cells) or immortalized cell lines (RAW264.7, RAW
ticity of the HSPs (Srivastava et al., 1994). We have 309Cr.1 macrophage, P815 mastocytoma, YAC-1 lym-
phoma, EL4 thymoma, Meth A and PS-C3H fibrosarco-
mas, B16 melanoma, CT26 colon carcinoma, and UV6139* To whom correspondence should be addressed (e-mail: srivastava@
nso2.uchc.edu). squamous cell carcinoma), as described in Experimental
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Table 1. Specific Binding of HSPs and a2 Macroglobulin to Primary Cultures and Cell Lines of Several Histological Originsa
bPercentage of Cells Binding with FITC-Labeled:
Cells Cell Type Haplotype a2M gp96 hsp70 hsp90 SA
B16 melanoma b 0.1 3.5 6.4 8.0 0.3
CT26 carcinoma d ND 0.3 3.1 5.5 0.4
YAC-1 lymphoma b 0.1 3.1 23.0 5.0 0.2
EL4 T cell thymoma b 0.1 2.9 3.0 6.6 1.0
Meth A sarcoma d 0.1 0.1 1.5 0.9 0.5
PS-C3H fibrosarcoma k 0.1 0.1 2.0 0.3 0.3
UV6139 sarcoma k 11 0.0 0.7 0.2 1.5
P815 mastocytoma d 0.1 1.1 1.7 0.7 0.2
Peritoneal cells macrophage d 90 97 82 82 11
BM-DCs dendritic cells b and d 1d 1d 1d 1d 2
RAW264.7c macrophage d 76 82 85 90 8.0
RAW309Cr.1c macrophage b 3 d 0.1 0.1 0.1 0.1 0.1
a Cells were incubated with FITC-labeled a2M, gp96, hsp70, hsp90, or SA. After removal of excess protein by extensive washing, cells were
analyzed for FITC staining by flow cytometry.
b Indicates percentage of cells staining with FITC over background staining with FITC alone.
c See Figure 1.
d Cells were examined by confocal microscopy. All CD11c1 cells were intensely positive for binding to the three HSPs and a2M.
Procedures. After removal of unbound protein by exten- HSP in a manner comparable to the binding observed
with RAW264.7. YAC-1 was observed to bind hsp70 butsive washing, cells were analyzed by flow cytometry.
As shown in Table 1, the peritoneal macrophages and only to a significantly smaller degree. The binding was
only a fraction of that observed with APCs.the bone marrow–derived dendritic cells showed robust
binding of each of the three HSPs but not albumin. CD91 or the a2 macroglobulin receptor has been iden-
tified recently as the receptor for gp96. All of the cellHowever, of the two macrophage cell lines, only one of
them, RAW264.7, bound the three HSPs. RAW309Cr.1 types in Table 1 were also tested for the presence of
CD91 by staining with FITC-a2 macroglobulin. CD91did not bind any of the HSPs (Figures 1A and 1B). Out
of eight other cell lines tested with the FITC-labeled showed precisely the same pattern of distribution as
did each of the three HSPs (Table 1).gp96, hsp90, and hsp70, none was observed to bind to
Figure 1. RAW264.7 but Not RAW309Cr.1 Binds Specifically to HSPs
The macrophage cell lines RAW264.7 (A) or RAW309Cr.1 (B) were incubated with 100 mg/ml of FITC-labeled gp96, hsp90, hsp70, or SA.
Excess protein was removed by extensive washing. Cells were analyzed by flow cytometry for the presence of FITC-labeled cells. Live cells
only were gated based on FSC.
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The Ability of Cells to Bind HSPs and a2M shown recently to be re-presented by APCs (Castellino
et al., 2000). The ability of other HSPs, hsp90, and CRTCorrelates with the Ability to Re-Present
gp96-Chaperoned Peptides to introduce chaperoned peptides into the endogenous
presentation pathway was tested in the AH1 systemWe tested if the ability of a particular cell type to bind
HSPs or a2 macroglobulin, as shown in Table 1, corre- with RAW264.7 cells as the APCs. RAW264.7 cells were
pulsed with hsp90, hsp70, CRT, or gp96, as a positivelates with its ability to re-present gp96-chaperoned pep-
tides. Re-presentation studies are done typically by in- control, by themselves, or chaperoning the AH1/19 pep-
tide. Chaperoning of peptides by the HSPs was accom-cubating APCs and an HSP, chaperoning a known
peptide, with T cells specific for an epitope present in plished in vitro as previously described (Blachere et al.,
1997; Basu and Srivastava, 1999). T cells specific for Ld/the chaperoned peptide (Suto and Srivastava, 1995).
The experimental system is set up such that the peptide AH1 secreted IFN-g when the RAW264.7 cells were pulsed
with complexes of hsp90, hsp70, CRT, or gp96 with AH1/cannot charge directly onto MHC class I but requires
intracellular processing followed by presentation to T 19 but not when the HSPs were not complexed with the
peptide (Figure 4). Pulsing of RAW264.7 cells with AH1/cells. VSV8 and AH1 antigenic systems were used in
these studies. The VSV8 epitope (RGYVYQGL) is pre- 19 alone did not lead to surface loading of Ld mole-
cules and consequent stimulation of T cells. Further,sented by the Kb molecule, and VSV19 (SLSDL RGY-
VYQGLKSGNVS) is its extended variant, which cannot RAW264.7 cells pulsed with complexes of serum albu-
min with AH1/19 also failed to stimulate Ld/AH1-specificcharge Kb directly. AH1 (SPSYVYHQF) is an Ld-restricted
epitope of a murine leukemia virus envelope protein T cells, thus indicating the specific requirement of HSPs
for introducing the chaperoned peptides into the endog-gp70 (Huang et al., 1996), and AH1/19 (RVTYHSPSY-
VYHQFERRAK) is its extended version. Peritoneal mac- enous presentation pathway (Figure 4).
rophage and BM-DCs were tested side by side for re-
presentation in the VSV8 system, and both cell types gp96, hsp90, hsp70, and CRT Engage
were able to re-present gp96-chaperoned VSV19 to a Common Receptor
VSV8-specific T cells (Figure 2A). EL4 and B16 cells, Does each HSP have a unique receptor, or do they share
both of the b haplotype, were also tested and were a common receptor? This question was addressed by
found unable to re-present in identical assays (data not three independent criteria: by measuring re-presenta-
shown). The BM-DCs appear to re-present gp96-chap- tion of gp96-chaperoned AH1/19 (as in Figures 2–4) in
eroned VSV19 better than macrophage did, although the presence of excess and titrated quantities of free
the difference may not be significant. Further, it is not (i.e., not complexed to AH1/19) gp96, hsp90, hsp70, or
possible to determine from the data if this difference serum albumin; by testing if a2 macroglobulin, a known
derives from the better T cell stimulatory properties of ligand for CD91, a receptor for gp96, can inhibit re-
DCs in general or whether the DCs are specifically more presentation of peptides chaperoned by gp96, hsp90,
efficient than macrophage at re-presenting gp96-chaper- hsp70, or CRT; and, finally, if anti-CD91 antibody can
oned peptides. The two macrophage cell lines RAW309Cr.1 inhibit re-presentation of peptides chaperoned by some
and RAW264.7 were tested for their re-presentation or all of the HSPs.
ability in the AH1 system. In parallel with the HSP and The gp96-AH1/19 complex was added to RAW264.7
a2M staining data (Table 1), RAW264.7 cells but not cultures at a fixed final concentration of 40 mg/ml, while
RAW309Cr.1 cells were observed to be capable of re- the competing HSPs or serum albumin were added at
presenting gp96-chaperoned AH1 peptides (Figure 2B). concentrations between 200 and 800 mg/ml. It was ob-
We compared the gp96 binding and the re-presenting served (Figure 5A) that all three competing HSPs could
ability of immature and mature DCs (Figure 3). Cultures inhibit re-presentation of gp96-chaperoned AH1/19, al-
of freshly isolated immature BM-DC were pulsed with beit with different efficiencies. gp96 was able to com-
medium alone or LPS as a maturation signal. The cul- pete with itself, while hsp90 was an even better competi-
tures were stained for gp96 binding and for expression tor than gp96. hsp70 was a less efficient competitor
of CD40 and CD11c. As expected, CD40 expression in than gp96 but was a significant competitor. Albumin
the mature DC cultures was significantly higher than in competed inefficiently. In quantitative terms, z2-fold
the immature DC cultures, while CD11c expression was molar excess of hsp90, 6-fold molar excess of gp96,
unchanged (Figure 3A, top). Comparison of gp96 binding and a 13-fold molar excess of hsp70 were required to
between immature and mature DC cultures, on the other inhibit by 50% the re-presentation of gp96-chaperoned
hand, failed to show any differences between the two peptides at a gp96 concentration of 40 mg/ml. All three
populations (Figure 3A, bottom). The immature and ma- HSPs were able to inhibit the re-presentation of gp96-
ture BM-DC cultures were also tested functionally for chaperoned peptides completely at the highest concen-
their ability to re-present gp96-chaperoned AH1/19 and tration tested. This observation suggests that gp96,
were found to be similar in that respect (Figure 3B). The hsp90, and hsp70 utilize a single receptor, albeit with
results from gp96 binding and functional re-presentation differing specificities.
studies were thus consistent with each other. In additional experiments, increasing quantities of a2
macroglobulin were added to re-presentation assays
where AH1/19 chaperoned by gp96, hsp90, hsp70, orPeptides Chaperoned by hsp90, hsp70,
and CRT Are Re-Presented by MHC CRT was re-presented by RAW264.7 cells to Ld/AH1-
specific T cells. a2 macroglobulin was observed to in-Class I Molecules of APCs
gp96 was the first HSP for which the re-presentation hibit, in a titratable manner, re-presentation of peptides
chaperoned by each of the four HSPs (Figure 5B). Re-phenomenon was experimentally shown (Suto and Sri-
vastava, 1995). Hsp70-chaperoned peptides have been presentation of peptides chaperoned by gp96, hsp70,
Immunity
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Figure 2. Re-Presentation of gp96-Chaper-
oned Peptides by APCs that Bind HSPs and
a2 Macroglobulin
(A) Peritoneal macrophage or BM-DCs from
C57Bl/6 mice (1 3 104) were pulsed with gp96
(40 mg/ml) by itself or complexed to the VSV19
peptide and used to stimulate the VSV8-spe-
cific CTL line (1 3 104) for 20 hr at 378C. Cul-
ture supernatants were tested for the pres-
ence of IFN-g (pg/ml) as a marker for CTL
stimulation.
(B) RAW264.7 or RAW309Cr.1 macrophage
lines were cultured with gp96 (40 mg/ml) by
itself or complexed to the AH1/19 peptide and
used to stimulate AH1-specific CTLs (1 3 104)
for 20 hr at 378C. Culture supernatants were
tested as in (A).
and CRT was inhibited equally, while re-presentation cated (Figure 5C). Anti-CD91 antibody was observed to
inhibit, titratably and specifically, the re-presentation ofof hsp90-chaperoned peptide was inhibited the most
effectively and almost completely at the highest concen- AH1 chaperoned by each of the four HSPs tested. The
isotype control antibody did not inhibit re-presentationtration of a2 macroglobulin tested. Serum albumin, when
tested at the highest concentration, inhibited re-presen- in any instance. Further, the inhibition mediated by the
anti-CD91 antibody was complete and uniform for eachtation only modestly. It may be noted that, while the
data in Figure 5A show that the specific peptide-defi- of the HSPs, indicating that CD91 is the sole receptor
for each of the four HSPs.cient HSPs inhibited re-presentation of gp96-AH1/19
complexes completely at the highest concentrations
tested, a2 macroglobulin appears far less effective, in Requirement of a Functional Proteasome Complex
for the Re-Presentation of gp96-Chaperonedquantitative terms, at inhibiting the re-presentation of
peptides chaperoned by three of the four HSPs (Figure Peptides by APCs
The re-presentation assay was carried out in the pres-5B). However, this quantitative disparity disappears if
one notes that the a2 macroglobulin molecule is z10 ence or absence of the specific proteasome inhibitor
lactacystin. The peritoneal macrophages were treatedtimes larger in molecular mass than the average HSP
molecule. or untreated with lactacystin for 2 hr and then cultured
with gp96-VSV19 complex for another 2 hr in the pres-A mouse monoclonal anti-CD91 IgG1 antibody and
isotype control antibodies were tested for their ability ence or absence of the inhibitor. The cells were chro-
mium labeled at the same time for 1 hr and then washedto inhibit re-presentation of peptides chaperoned by
gp96, hsp90, hsp70, and CRT. As before, the RAW264.7/ and used as targets against CD81 T cells specific for
VSV8, in a 4 hr chromium release assay. Gp96-VSV19,AH1 system was utilized, and the antibodies were added
to re-presentation cultures at the concentrations indi- lactacystin-untreated pulsed APCs were lysed by VSV8-
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Figure 3. Comparison of Immature and Mature BM-DCs with Respect to Binding of gp96 and Ability to Re-Present gp96-Chaperoned Peptides
(A) (Top) BM-DC cultures in medium without (left) or with (right) LPS were stained for expression of CD11c and CD40. Enhanced expression
of CD40 is seen on the mature DC cultures. (Bottom) Both cultures were also stained for gp96 binding and expression of CD11c. No differences
were detected between the immature and mature DC cultures.
(B) BM-DC cultures were pulsed with medium alone or LPS as a maturation signal or with serum albumin as a negative control. All cultures
were tested for re-presentation of gp96-chaperoned AH1/19 as described in Figure 2.
specific CD81 T cells (Figure 6A). As observed previously peptides is still unclear. However, and regardless of
this observation, the lactacystin-treated, gp96-VSV19for gp96 (Suto and Srivastava, 1995) and for hsp70
(Castellino et al., 2000), only a small proportion of pulsed pulsed APCs were not recognized by the VSV8-specific
CD81 T cells and were not lysed by them (Figure 6A).APCs were lysed by the APCs, even at the highest E:T
ratio tested (Figure 6A). The T cells pulsed with VSV8 Inhibition of proteasomal function thus inhibits the pro-
cessing of peptides chaperoned by gp96. As other HSPs(through surface charging) were lysed in a titratable and
more significant degree, indicating that the APCs were tested also use the same portal of entry (Figure 5), it is
assumed that inhibition of proteasome function inter-entirely capable of being lysed. The basis of the selec-
tive lysability of APCs re-presenting HSP-chaperoned feres with processing of peptides chaperoned by them
Immunity
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Figure 4. Peptides Chaperoned by hsp90, CRT, hsp70, and gp96 but Not Serum Albumin Are Re-Presented by RAW264.7 Cells
The chaperones, uncomplexed or complexed to the AH1/19 peptide, were used to pulse RAW264.7 cells, which were tested for their ability
to stimulate cognate CTLs, as described in the legend to Figure 2B. The unchaperoned AH1/19 did not stimulate the CTLs.
as well. The data recently reported by Castellino et al. [51Cr]EL4 cells or EL4 cells pulsed with the VSV8 peptide
as targets. Spleen cells of wild-type (C57BL/6) mice(2000) for hsp70 are consistent with this inference.
immunized with gp96-peptide complex showed VSV8-
specific CTL activity, whereas splenocytes of TAP12/2Re-Presentation of gp96-Chaperoned Peptides
mice immunized with gp96-peptide complex showed noby MHC Class I of the APCs Requires
cytotoxic activity (Figure 6C). It may be argued that thea Functional TAP
lack of CTL activity in TAP2/2 mice is a result of the poorThe requirement of TAP in re-presentation of gp96-
loading and stability of MHC class I molecules in general,chaperoned peptides by APCs was tested. In a re-pre-
rather than because of a specific block in re-presenta-sentation assay in vitro, gp96 purified from liver or the
tion. While this is possible and is difficult to entirelysame gp96 complexed with VSV19 was pulsed onto
refute, we are easily able to generate VSV8-specificprimary cultures of peritoneal macrophages or BM-DCs
CTLs in TAP2/2 mice, as in TAP1/1 mice, by immunizationderived from TAP1/1 or TAP2/2 mice. The pulsed macro-
with VSV8 peptide in incomplete Freund’s adjuvant (Fig-phage or BM-DCs were used to stimulate CD81 T cell
ure 6D). Sandberg et al. (1996) have reported similarlines specific for Kb/VSV8. After incubation for 20 hr, the
data. In any case, the data from re-presentation assaysculture supernatants were tested for release of IFN-g,
in vitro using APCs from TAP1/1 and TAP2/2 mice (Figureas a marker for T cell stimulation (Figure 6B). It was
6B) demonstrate the TAP requirement for re-presenta-observed that APCs from TAP1/1 mice stimulated the
tion without the complexity introduced by the experi-CD81 T cells specifically when cultured in the presence
ment in vivo (Figure 6C).of gp96 complexed to VSV19, but APCs from TAP12/2
mice were unable to do so. There were no detectable
differences between the data with macrophage and Discussion
DCs. This result indicates that gp96-chaperoned pep-
tides must enter the endoplasmic reticulum through the A receptor for HSPs was originally envisaged in order
to explain the extraordinary immunogenicity of HSP-TAP molecules for being loaded on the MHC class I mole-
cules. As other HSPs tested also use the same portal of peptide complexes; very small quantities of antigenic
peptides, if associated with HSPs, could elicit antigen-entry (Figure 5), it is assumed that peptides chaperoned
by other HSPs also require TAP for re-presentation. Part specific T cell responses in mice, and, in spite of the
exogenous administration, the response was CD81 andof the data recently reported by Castellino et al. (2000)
for hsp70 are consistent with this inference. MHC class I–restricted (Srivastava et al., 1994). The
HSPs that could chaperone peptides and immunizeIn studies in vivo, TAP12/2 (C57BL/6/SV129J) or wild-
type (C57BL/6) mice were immunized with the gp96- were first restricted to gp96 (Srivastava, 1982; Srivas-
tava and Das, 1984; Srivastava et al., 1986), but soonVSV19 complexes (50 mg gp96) or VSV19 alone or gp96
alone. Spleen cells of immunized mice were cultured the list grew longer and came to include hsp90 (Ullrich
et al., 1986, Udono and Srivastava, 1994), hsp70 (Udonowith the VSV8 and tested for cytotoxic activity on
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Figure 5. gp96, hsp90, hsp70, and CRT Uti-
lize a Common Receptor for Re-Presentation
(A) RAW264.7 cells were pulsed with gp96-
AH1/19 complexes (40 mg/ml gp96) in the
presence of increasing concentrations of un-
complexed gp96, hsp90, hsp70, or SA, as in-
dicated. Re-presentation assay was carried
out as described in the legend to Figure 2B.
(B) Re-presentation of AH1/19 complexed to
gp96, hsp90, hsp70, CRT, or albumin (as de-
scribed in [A]) was carried out in the presence
of increasing concentrations of a2 macro-
globulin, a previously known ligand for CD91.
As the re-presentation efficiency of each HSP
was different (see Figure 4), the data are plot-
ted as percentage inhibition of re-presen-
tation.
(C) Re-presentation of AH1/19 complexed to
gp96, hsp90, hsp70, or CRT (as described in
[A]) was carried out in the presence of in-
creasing concentrations of anti-CD91 anti-
body, as indicated. As the re-presentation ef-
ficiency of each HSP was different (see Figure
4), the data are plotted as percentage inhibi-
tion of re-presentation.
and Srivastava, 1993), CRT (Basu and Srivastava, 1999), tors for HSPs such as hsp60 that do not bind peptides
and do not prime T cell responses. The toll-like receptorand, most recently, hsp110 and grp170 (Wang et al.,
2000). The receptor for gp96 was recently identified as 4 on APCs has been implicated in such interaction
(Ohashi et al., 2000). The role for CD91 in interaction ofCD91, an a2 macroglobulin receptor. The studies shown
here indicate that this receptor is also engaged by other HSPs and APCs remains to be examined.
The observations that a2 macroglobulin and anti-CD91hsp90, hsp70, and CRT. This observation is surprising
in light of the fact that hsp70, CRT, and hsp90/gp96 antibodies inhibit re-presentation by each of the four
HSPs completely indicate that CD91 is the only receptorhave no obvious structural similarities with each other.
In another context, HSPs have presented us with this involved in re-presenting peptides chaperoned by any
of the four HSPs tested. Considering the increasinglydilemma before: many of the various HSPs have no
obvious homologies with each other, and yet they ap- obvious role that the HSPs play in innate (Basu et al.,
2000) and adaptive immune response, this observationpear to bind many of the same peptides (Breleor et al.,
1998; Ishii et al., 1999). It remains to be seen if hsp110, is somewhat counterintuitive. However, the data on
complete inhibition by two independent means (Figurewhich belongs to the extended hsp70 family, and
grpp170, which has no homology to any of the other 5) are compelling. We have noticed earlier and we report
here significant differences between hsp70 and hsp90/HSPs, shall share the CD91 receptor. The multiple com-
mon properties of the HSPs that share the fourth para- gp96 in their ability to compete for binding to gp96
receptors (Binder et al., 2000b). Arnold-Schild et al.digm (Srivastava, 1994) (i.e., peptide binding, interacting
with APCs through a common receptor, ATP binding, (1999) have also observed similar differences between
gp96 and hsp70. These differences are not inconsistentand ATPase activity) strongly suggest that these mole-
cules share conformational similarities that are not obvi- with our present report pointing to a single receptor for
the four HSPs. They simply suggest that the variousous from their primary sequence. Crystallographic anal-
yses of hsp70 and hsp90 have begun to reveal their HSPs interact with a single receptor with widely differing
affinities. Castellino et al. (2000) have recently demon-structure (Zhu et al., 1996; Prodromou et al., 1997; Steb-
bins et al., 1997) and shall shed light on this question. strated re-presentation of hsp70-chaperoned peptides
by APCs through receptor-mediated uptake and haveAn interesting and related question has to do with recep-
Immunity
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Figure 6. Re-Presentation of gp96-Chaperoned Peptides Follows the Classical Endogenous Antigen Presentation Pathway
(A) Requirement of proteasomes. Peritoneal macrophage (1 3 106 ) were either treated or untreated with lactacystin (100 mM) for 2 hr at room
temperature and then pulsed with gp96-VSV19 complex (40 mg/ml) or gp96 alone for another 2 hr at 378C. The cells were labeled with chromium
and used as targets against VSV8-specific CTLs.
(B) Requirement of TAP as measured in vitro. Peritoneal macrophage or BM-DCs (as indicated) from TAP1/1 or TAP2/2 mice were cultured
with gp96 (40 mg/ml) from liver or gp96-VSV19 complex (40 mg/ml) and VSV8-specific CTL line for 20 hr at 378C. Culture supernatants were
tested for the presence of IFN-g (pg/ml) as a marker for CTL stimulation.
(C) Requirement of TAP as measured in vivo. Gp96-VSV19 complex (50 mg gp96) was injected intraperitoneally. After 10 days, spleens were
removed, and cells were cultured in vitro with VSV8. The lymphocyte cultures were tested for their ability to lyse EL4 cells (dotted line) or EL4
cells pulsed with VSV8 peptide (solid line). Each line represents one mouse.
(D) TAP2/2 mice can generate VSV8-specific CTLs. TAP1/1 and TAP2/2 mice were immunized with VSV8 (100 mg) in incomplete Freund’s
adjuvant, and splenocytes of immunized mice were tested for their ability to lyse EL4 cells (open symbols) or VSV8-pulsed EL4 cells (closed
symbols). Two mice were tested in each group, and data for both mice are shown.
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suggested the existence of receptors of different affinity vations show that the peptides go from the endosome
classes for single HSPs. That argument is biologically to the cytosol to the ER and then to the secretory path-
cogent but is not supported by our present data. way to be re-presented on the surface. The transit
The question of single or multiple receptors cannot through the cytosol is established through the protea-
be addressed fully without taking into consideration one some requirement as well as through the apparent TAP
other consequence of HSP-APC interaction. We have requirement of re-presentation. There is no known
focused our attention thus far on the ability of HSPs to mechanism for transit of molecules from vesicular to
bind the cognate receptors on APCs, for the HSP-pep- soluble compartment, although precedents certainly ex-
tide complexes to be internalized, and for the peptides ist (Chiang et al., 1989). Exploration of this pathway shall
chaperoned by them to be re-presented by the MHC without doubt open a new window into our understand-
class I molecules of the APCs. However, HSP-APC inter- ing of the intracellular traffic of proteins. Castellino et
action has an additional consequence: engagement of al. (2000) have reported recently on the events as they
APCs by HSPs activates them to release a number of occur downstream of receptor-mediated uptake of
cytokines and to cause expression of antigen-present- hsp70-peptide complexes by APCs. Our observations
ing and costimulatory molecules on them (Basu et al., with a different HSP (gp96) are entirely consistent with
2000). In the case of DCs, these phenomena may be that version of events and buttress the notion that the
grouped into the category of a maturation signal. Are same portal of entry is used by all the peptide-chaper-
the receptors involved in re-presentation the same as oning HSPs for re-presentation.
are necessary for the innate aspects of the HSP-APC All the studies on HSP-mediated peptide re-presenta-
interaction? Our present studies do not shed light on tion have relied thus far on PEMs and, more recently,
this question. It is unclear if the CD91 is a signaling BM-DCs as the APCs. The demonstration that a perma-
receptor (Goretzki and Mueller, 1998) or if HSPs interact nent, easily available, and easily cultured cell line of
with other signaling receptors to mediate the release of macrophage origin can re-present HSP-chaperoned
cytokines and related phenomena. Preliminary data peptides is an important contribution of this study. The
from our laboratory suggest that the scavenging recep- RAW264.7 line is of the d haplotype and, as such, of
tor CD36 is involved in activation of APCs by HSPs limited utility; however, its many variants expressing a
to release cytokines and chemokines (Panjwani et al., wide array of restriction elements of mouse and human
2000). origin are under construction and should become pow-
A number of APCs have been analyzed for their ability erful tools for biochemical, cell biological, and immuno-
to re-present HSP-chaperoned peptides. These include logical analysis of HSP-mediated re-presentation.
PEMs, immature and mature BM-DCs, and RAW264.7 Finally, a comment on the biological functions of the
cells. Somewhat surprisingly, we did not observe much HSP receptor is in order. We have reported recently that
heterogeneity among the APCs in their ability to re- HSPs are released from cells as a result of necrotic
present HSP-chaperoned peptides. Within the limits of death but not of apoptotic cell death (Basu et al., 2000).
our ability to quantitate the re-presenting ability, primary In this context, the identification of CD91 as the gp96
macrophages, a macrophage line, and immature and receptor lead us to suggest CD91 to be a sensor of
mature DCs were all able to re-present HSP-chaperoned necrotic cell death. Among the four HSPs tested here
peptides, although the BM-DCs appeared to re-present and, indeed, among all HSPs, hsp90 is the most abun-
with a detectably higher efficiency. This observation is dant on a per cell basis. It is also among the most
partly at variance with the recent report by Singh-Jasuja primitive HSPs. In this regard, we have been repeatedly
et al. (2000), who showed a dimunition of gp96 binding impressed with the observation that hsp90 is the most
in the BM-DCs as a function of their differentiation. The potent competitive inhibitor for binding of gp96 to APCs
most likely basis for the discrepancy between our results (Binder et al., 2000b) and for re-presentation of gp96-
and those of Singh-Jasuja et al. lies in the fact that
chaperoned peptides (this study). Viewing these obser-
we have used freshly isolated cultures (6 day) of bone
vations and considerations together, it is our opinion
marrow DCs as immature DCs and LPS-stimulated DCs
that hsp90, more than other HSPs, is the primary indica-as matured DCs. In contrast, Singh-Jasuja et al. have
tor of cell death and that CD91 is perhaps primarily aused long-term cultures of bone marrow DCs without
receptor for hsp90. Gp96, hsp70, and CRT (and presum-LPS stimulation as matured DCs. Obviously, culture
ably hsp110, an hsp70 family member) are able to useconditions can have profound influence on the status
CD91 as their receptor, by virtue of their obvious (in theof DCs. It is also conceivable that the difference arises
case of gp96) and nonobvious (in the case of others)simply from the sensitivity of the specific reagents used
homologies with hsp90. Clearly, this idea requires fur-(gp96-FITC) by Singh-Jasuja et al. (2000) and in the pres-
ther experimental exploration.ent study. Our functional studies using the re-presenta-
tion assay show that mature DCs are at least as efficient
as immature DCs in re-presenting gp96-chaperoned Experimental Procedures
peptides.
Mice, Cells, and ReagentsOnce the HSP-peptide complex binds to the receptor,
C57Bl/6, BALB/c, and TAP2/2 mice were obtained from Jacksonpeptides chaperoned by the HSPs must enter the APC
Laboratories. Bone marrow–derived DCs were generated from thealong with the HSP. The studies reported here address
femurs and tibia of C57BL/6 mice. The bone marrow was flushed
the downstream events solely with respect to gp96, in out, and the leukocytes were obtained and cultured, as described
the assumption that, if all HSPs enter through the same (Lutz et al., 1999), in complete RPMI1640 with 10% heat-inactivated
portal, the downstream events must be identical or simi- FCS and 20 ng/ml GMCSF (Endogen, Inc., Woburn, MA) for 6 days.
On day 3, fresh media with GMCSF was added to the plates for thelar for peptides chaperoned by each of them. Our obser-
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day 6 cultures. Macrophages were obtained from PEMs of pristaned grant CA64394 and by a research agreement with Antigenics, in
which P. K. S. has a significant financial interest.mice by positive selection for CD11b1 cells (Miltenyi Biotech, Inc.).
RAW264.7 was a gift of Dr. Christopher Nicchitta. A20.25 was a gift
of Dr. Lawrence Kwak. All other cell lines were obtained from ATCC. Received November 7, 2000; revised February 12, 2001.
Proteasome inhibitor Lactacystin was purchased from Kamiya, Inc.
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